News

Martin Lehr 6/2/25 Martin Lehr 6/2/25

A Phase 1, First-in-Human Study of CTIM-76, a Claudin-6 (CLDN6)-Directed Bispecific Antibody, in Patients with Recurrent Ovarian Cancer and Other Advanced Solid Tumors

Roisin E. O’Cearbhaill et al.

American Society of Clinical Oncology I Annual Meeting I Abstract TPS2685 I May 30-June 3, 2025

Martin Lehr 11/9/24 Martin Lehr 11/9/24

Determination of first in human dose of the T cell-redirecting bispecific antibody CTIM-76 targeting Claudin 6

Kelly Byrnes-Blake, Edward Calamai, Stanley Roberts, and Eric Butz

Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting I Abstract 1288 I November 7-11, 2024

Martin Lehr 11/3/23 Martin Lehr 11/3/23

CTIM-76, a Highly Specific Claudin 6 Antibody

Hayley Roth, Samantha Brady, Ileine Sanchez, Breanna Tyrell, Guangming Liu, Holden Ohl, Nicholas Molino, Eric Butz, Ed Calamai, Stanley Roberts, Kelly Byrnes-Blake, Kyle Doolan, Ross Chambers, and Joseph Rucker

Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting I Abstract 1183 I November 2-5, 2023